The purpose of this study is to determine whether dipyridamole enhances postocclusive reactive hyperaemia by increasing extracellular adenosine concentrations during ischemia and reperfusion. Furthermore we hypothesize that dipyridamole augments postocclusive reactive hyperaemia by increasing adenosine receptor stimulation...
Date First Received: December 21, 2005
Last Updated: March 27, 2008
Verified by: Radboud University, March 2008
Clinical Trial Phase: N/A | Start Date: December 2005
Overall Status: Completed
Estimated Enrollment: 12
Brief Summary
Official Title: “Enhancement of Postocclusive Reactive Hyperaemia”
Intervention(s):
The purpose of this study is to determine whether dipyridamole enhances postocclusive reactive hyperaemia by increasing extracellular adenosine concentrations during ischemia and reperfusion. Furthermore we hypothesize that dipyridamole augments postocclusive reactive hyperaemia by increasing adenosine receptor stimulation.
Study Type: Interventional
Study Design: Basic Science, Non-Randomized, Open Label, Placebo Control, Crossover Assignment
Intervention(s) in this Clinical Trial
- Drug: dipyridamole
- Drug: caffeine
Outcome Measures for this Clinical Trial
Primary Measures
- forearm blood flow
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- healthy volunteers between 18 and 50 years
Exclusion Criteria:
- none specified
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 50 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: Radboud University
Overall Clinical Trial Officials and Contacts
Gerard Rongen, MD,PhD Principal Investigator Radboud University
Additional Information
Information obtained from ClinicalTrials.gov on August 20, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00268554
Study ID Number: PORH-dipy
ClinicalTrials.gov Identifier: NCT00268554
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
